Clyde attending ACT conference (Nov 16-19, Phoenix, Arizona)

Clyde are attending ACT to engage with toxicologists regarding their human stem cell derived cardiomyocyte safety assay (CellOPTIQ®. The pharmaceutical industry has entered a new challenging phase, where political pressures have set about a roadmap for the reduction of animal experimentation, replacing them with in vitro human assay alternatives (NAMs).

For over a decade, Clyde has been central to developing and validating an in vitro human cardiomyocyte safety assay (CiPA Assay), working with the FDA and a range of large pharmaceuticals. Delivering studies to over 150 customers, Clyde has not only helped their clients manage cardiovascular risk better, and reduced costly late stage failures, but also reduced the number of animals used in cardiovascular safety testing.

Clyde will be engaging with many of the industries toxicologists at ACT and providing solutions to the current challenges and engaging in the ongoing debate.